Dr. Reddy's Laboratories, Aurigene Pharmaceutical Services, And Kainomyx Sign Non-Binding MoU For Joint Development Of Affordable Anti-Malarial Drug
Dr. Reddy's Laboratories, Aurigene Pharmaceutical Services, And Kainomyx Sign Non-Binding MoU For Joint Development Of Affordable Anti-Malarial Drug
- Malaria is a life-threatening public health issue, particularly in low- and middle-income countries. There is a need for an effective, affordable, and accessible preventive and/or treatment medication. This potential partnership is a step towards this cause
- This potential partnership aims to bring together Kainomyx's expertise in novel drug discovery, Aurigene's capability to conduct integrated drug discovery and development, and Dr. Reddy's ability to commercialize products in low and middle-income countries, in addition to the US and Europe
- It is a testament to the commitment of involved parties towards promoting global public health and Dr. Reddy's goal of reaching 1.5 billion patients by 2030
- 疟疾是一项威胁公共健康的问题,特别是在低收入和中等收入国家。需要一种有效、实惠和可访问的预防和/或治疗药物。这种潜在的伙伴关系是迈向这个目标的一步。
- 这种潜在的伙伴关系旨在将Kainomyx的新药发现专业知识,Aurigene进行一体化药物发现和开发的能力以及Dr. Reddy在低收入和中等收入国家,以及美国和欧洲生产产品的能力结合起来。
- 它证明了各方致力于促进全球公共卫生和Dr. Reddy在2030年前达到15亿患者的目标的承诺。
Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's")), and its CRDMO arm Aurigene Pharmaceutical Services Limited (Aurigene), today announced that they have signed a non-binding Memorandum of Understanding (MoU) with Kainomyx, Inc., a US-based company with a proprietary platform that helps target cytoskeletal proteins of parasites, a novel mechanism of action, for the development and commercialization of affordable anti-malarial drug in the U.S., Europe, and in low and middle-income countries. The MoU remains subject to signing of a definitive agreement.
Dr. Reddy's Laboratories Ltd. ((BSE: 500124,NSE: DRREDDY,NYSE:RDY,NSEIFSC: DRREDDY,及其附属公司合称"Dr. Reddy's")和其CRDMO子公司Aurigene Pharmaceutical Services Limited (Aurigene)今天宣布,他们已经与Kainomyx签署了一份非约束性谅解备忘录(MoU),Kainomyx是一家总部位于美国的具有专有平台的公司,该平台有助于针对寄生虫细胞骨架蛋白的靶向作用,这是一种新颖的作用机制,用于开发和生产价格实惠的抗疟疾药物,在美国,欧洲以及低收入和中等收入国家。谅解备忘录仍待签署最终协议。